|
The total deal value of US licensing of innovator drug candidates from Chinese biopharma companies has surged 280% since 2020.
|
 |
|
The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.
|
|
|
A proteasome inhibitor, Boruzu references branded Velcade, a lyophilised powder that requires reconstitution prior to usage.
|
|
|
The sNDA application is based on the positive outcomes from the Phase III VALIANT trial at week 26.
|
|
|
GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.
|
|
|
The CNS market’s decade-long stagnation was driven by the high cost, complexity, and risk of drug development.
|
|
|
J&J will now reallocate $7bn of funds previously set aside for the bankruptcy resolution.
|
|
|
The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US Government to add to vaccine reserves.
|
|
